These new findings are consistent with overall results from the Horizons-AMI trial that demonstrate treatment with Angiomax resulted in superior net clinical outcomes and fewer cardiac deaths when compared to unfractionated heparin (UFH) plus a platelet glycoprotein IIb/IIIa inhibitor (GPI) in patients presenting with ST-segment elevation myocardial infarction (STEMI), the most severe form of heart attack. Reduced bleeding has been associated with greater long-term survival in other studies in angioplasty patients.
In the overall trial of 3,602 patients, Angiomax significantly improved net clinical adverse events by 24%, significantly reduced rates of major bleeding by 40%, demonstrated comparable rates of major adverse cardiac events, and significantly reduced the incidence of cardiac-related mortality by 38% when compared to the more complex regimen of UFH plus GPI 30 days following primary angioplasty.
John Kelley, president and COO of The Medicines Company, said: “These new data from Horizons-AMI add to the wealth of clinical experience that shows Angiomax consistently improves outcomes across the entire spectrum of risk in patients undergoing percutaneous coronary intervention. Given these results, we anticipate greater uptake of Angiomax by physicians worldwide.”